Volume 26, Number 8—August 2020
Research
Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar
Mwinyi Msellem, Ulrika Morris, Aungpaing Soe, Faiza B. Abbas, Abdul-Wahid Ali, Rory Barnes, Paolo Frumento, Abdullah S. Ali, Andreas Mårtensson, and Anders Björkman
Table 1
Characteristics of patients in 3 clinical trials testing increased sensitivity of Plasmodium falciparum to artesunate/amodiaquine despite 14 years as first-line malaria treatment, Zanzibar
| Characteristic | Study group |
||
|---|---|---|---|
| 2002–2003 | 2005 | 2017 | |
| No. screened* | 2,097 | 2,076 | 9,062 |
| No. enrolled | 207 | 177 | 146 |
| M:F ratio | 104:103 | 82:95 | 101:45 |
| Median age (range) | 24 (5–73) mo | 28 (4–60) mo | 16 (2–60) y |
| Geometric mean parasite density per microliter (range) | 19,731 (2,000–198,000) | 20,890 (2,000–176,000) | 7,886 (75–304,000) |
| Mean ± SD temperature, °C | 38.7 ± 1.2 | 37.8 ± 1.2 | 37.8 ± 1.4 |
| Mean ± SD hemoglobin level, g/dL | 8.5 ± 1.6 | 9.2 ± 1.4 | 11.9 ± 2.2 |
*Febrile patients attending healthcare facilities with suspected uncomplicated P. falciparum malaria infections.
Page created: May 26, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.